TTNP · Titan Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - | $424.0K | $442.0K | $561.0K |
| SG&A | $657.0K | $534.0K | - | $754.0K | $2.07M | $1.06M | - | $1.64M | $1.23M | $1.23M |
| Total Operating Expenses | $657.0K | $534.0K | - | $754.0K | $2.07M | $1.06M | - | $2.06M | $1.67M | $1.79M |
| D&A | - | - | - | - | - | $2.0K | - | - | - | $43.0K |
| Operating Income | ($657.0K) | ($534.0K) | - | ($754.0K) | ($2.07M) | ($1.06M) | - | ($2.06M) | ($1.59M) | ($1.70M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($689.0K) | ($563.0K) | - | ($763.0K) | ($2.09M) | ($1.06M) | - | ($338.0K) | ($1.59M) | ($1.68M) |
| EPS - Basic | ($0.65) | ($0.62) | - | ($0.83) | ($2.29) | ($1.24) | - | ($0.18) | ($0.11) | - |
| EPS - Diluted | ($0.65) | ($0.62) | - | ($0.83) | ($2.29) | ($1.24) | - | ($0.02) | ($0.11) | ($0.24) |
Balance Sheet
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.80M | $1.95M | $2.83M | $3.40M | $4.09M | $6.16M | $6.76M | $8.10M | $105.0K | $1.14M |
| Accounts Receivable | - | - | - | $38.0K | $38.0K | $134.0K | $46.0K | $26.0K | $9.0K | $8.0K |
| Inventory | - | - | - | - | - | - | $0 | - | - | $106.0K |
| Accounts Payable | $219.0K | $194.0K | $202.0K | $371.0K | $356.0K | $371.0K | $348.0K | $407.0K | $597.0K | $567.0K |
| Current Assets | $3.05M | $2.16M | $2.92M | $3.60M | $4.35M | $6.61M | $8.02M | $9.90M | $498.0K | $1.78M |
| Total Assets | $3.05M | $2.16M | $2.92M | $3.60M | $4.35M | $6.65M | $8.09M | $10.00M | $812.0K | $2.17M |
| Current Liabilities | $263.0K | $279.0K | $483.0K | $371.0K | $356.0K | $559.0K | $1.44M | $1.87M | $1.85M | $2.45M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $263.0K | $279.0K | $483.0K | $371.0K | $356.0K | $559.0K | $1.44M | $1.87M | $1.85M | $2.48M |
| Stockholders' Equity | $2.79M | $1.88M | $2.44M | $3.23M | $3.99M | $6.09M | $6.64M | $8.13M | ($1.03M) | ($312.0K) |
| Retained Earnings | ($397.79M) | ($397.10M) | ($396.54M) | ($395.75M) | ($394.98M) | ($392.89M) | ($391.83M) | ($389.86M) | ($389.52M) | ($387.94M) |
Cash Flow
| Line item | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($867.0K) | - | - | - | ($613.0K) | - | - | - | ($1.90M) |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | ($19.0K) | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -22.6% | -26.1% | - | -21.2% | -48.1% | -15.9% | - | -3.4% | -195.3% | -77.3% |
| Return on equity | -24.7% | -30.0% | - | -23.6% | -52.4% | -17.4% | - | -4.2% | 153.4% | 536.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 11.60 | 7.73 | 6.05 | 9.71 | 12.22 | 11.83 | 5.55 | 5.30 | 0.27 | 0.73 |
| Quick ratio | 11.60 | 7.73 | 6.05 | 9.71 | 12.22 | 11.83 | 5.55 | 5.30 | 0.27 | 0.69 |
| Cash ratio | 10.66 | 6.97 | 5.86 | 9.16 | 11.49 | 11.02 | 4.68 | 4.34 | 0.06 | 0.46 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.09 | 1.15 | 1.20 | 1.11 | 1.09 | 1.09 | 1.22 | 1.23 | -0.79 | -6.95 |
| Liabilities / Assets | 0.09 | 0.13 | 0.17 | 0.10 | 0.08 | 0.08 | 0.18 | 0.19 | 2.27 | 1.14 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 68.3% | 49.8% | - | 63.4% | -30.6% | 37.4% | - | 22.0% | 35.0% | 33.2% |
| Net income growth (YoY) | 67.1% | 46.9% | - | -125.7% | -32.0% | 36.7% | - | 87.2% | 35.6% | 34.1% |
| EPS growth (YoY) | 71.6% | 50.0% | - | -4050.0% | -1981.8% | -416.7% | - | 88.9% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -30.2% | -69.2% | -63.3% | -60.3% | - | - | 387.3% | 129.1% | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing TITAN PHARMACEUTICALS INC against the 5 most active filers in the same SIC group.